International journal of cardiology. Cardiovascular risk and prevention

Comparing combined GLP-1 and SGLT2 treatments to GLP-1 alone for heart rhythm issues in non-diabetic obese patients over time

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) are increasingly used together in patients without diabetes.

  • Both GLP-1RAs and SGLT2is have known benefits for heart and metabolic health.
  • The combined effects of these medications on heart rhythm disturbances are not well understood.
  • Research on cardiac arrhythmias in non-diabetic obese patients is limited.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Related papers

Apr '25
How well newer GLP-1RA drugs work when added to SGLT2i treatment in type 2 diabetes
top 2% journal
cited by 25 papers
comparative study
Oct '25
Heart and kidney results of combining two diabetes drugs: GLP-1 receptor agonists and SGLT2 inhibitors
top 2% journal
cited by 5 papers
systematic review
Nov '24
Heart and kidney effects of combining GLP-1 receptor drugs with SGLT2 inhibitors in real-world studies
top 10% journal
cited by 11 papers
journal article
Jun '22
Risk of new atrial fibrillation in type 2 diabetes patients using three common diabetes medicines
top 2% journal
cited by 39 papers
research support, non-u.s. gov't
Dec '25
Glucagon-like peptide-1 drugs and heart event risks in older adults taking thyroid medicine
top 2% journal
cited by 4 papers
observational study
Jan '24
Glucagon-like peptide-1 drugs and the risk of irregular heartbeat in adults with diabetes: a real-world study
top 5% journal
cited by 21 papers
journal article
Apr '26
Outcomes of Semaglutide and SGLT2 Inhibitors in Diabetic Patients After a Heart Attack
top 50% journal
journal article
Feb '23
Stroke and irregular heartbeat risks linked to diabetes drugs GLP-1 receptor agonists versus SGLT2 inhibitors in Hong Kong patients
top 2% journal
cited by 19 papers
journal article
Apr '25
Combining SGLT2 inhibitors and GLP-1 receptor agonists linked to better heart outcomes in type 2 diabetes patients after a heart attack
top 20% journal
cited by 17 papers
journal article
May '24
How previous diabetes treatments affect kidney and heart results of combined SGLT2 inhibitor and GLP-1 receptor agonist therapy in type 2 diabetes with chronic kidney disease
cited by 6 papers
journal article

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
2 days ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
1 week ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
2 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
3 weeks ago7 studies
issue #44
Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study
4 weeks ago7 studies
issue #43
Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients
5 weeks ago7 studies
issue #42
Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group
6 weeks ago8 studies
issue #41
New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients
7 weeks ago7 studies
issue #40
GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery
8 weeks ago7 studies
issue #39
Semaglutide linked to reduced cigarette craving in 24 smokers
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief